Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 6/20 | 0.69 |
| ▸ | CA2 | P00918 | 6/20 | 0.69 |
| ▸ | CA12 | O43570 | 5/20 | 0.69 |
| ▸ | CA7 | P43166 | 5/20 | 0.69 |
| ▸ | CA9 | Q16790 | 5/20 | 0.69 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.69 |
| ▸ | XDH | P47989 | 2/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.57 |
| ▸ | GFER | P55789 | 1/20 | 0.57 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.57 |
| ▸ | RELA | Q04206 | 1/20 | 0.57 |
| ▸ | FUT7 | Q11130 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | HPGD | P15428 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29732333 | 1.00 | CA1 (0.69) | CA1CA2CA12CA7CA9 | |
| SCHEMBL5847115 | 0.86 | EGFR (0.63) | CA1CA2CA12CA7CA9 | |
| SCHEMBL944597 | 0.85 | CA1 (0.69) | CA1CA2CA12CA7CA9 | |
| SCHEMBL550572 | 0.84 | CA1 (0.57) | CA1CA2CA12CA7CA9 | |
| Methyl Protocatechuate SCHEMBL29360855 | 0.82 | CA1 (1.00) | CA1CA2CA12CA7CA9 | |
| SCHEMBL15099889 | 0.82 | CA1 (0.77) | CA1CA2CA12CA7CA9 | |
| Methyl Protocatechuate SCHEMBL38624 | 0.82 | CA1 (1.00) | CA1CA2CA12CA7CA9 | |
| SCHEMBL31525599 | 0.81 | CA12 (0.59) | CA1CA2CA12CA7CA9 | |
| SCHEMBL1459771 | 0.81 | TDP1 (0.53) | CA1CA2CA12CA7CA9 | |
| SCHEMBL27707943 | 0.81 | KDM4E (0.58) | CA1CA2CA12CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 343 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119059895-A | Preparation method of 2,2 '-dihydroxybiphenyl-4, 4' -dicarboxylic acid | 黑龙江省科学院石油化学研究院 | 2024-12-03 | — | — | CN | claimed |
| CN-114315885-B | Method for catalytic synthesis of methyl 3-hydroxy-4- ((trimethylsilyl) ethynyl) benzoate | 山东金城柯瑞化学有限公司 | 2024-05-03 | — | — | CN | claimed |
| CN-114315885-A | Method for catalytically synthesizing methyl 3-hydroxy-4- ((trimethylsilyl) ethynyl) benzoate | 山东金城柯瑞化学有限公司 | 2022-04-12 | — | — | CN | claimed |
| US-20260062443-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMA INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-20260001886-A1 | ENPP1 INHIBITORS I | RE VENTURES I LLC (US) | 2026-01-01 | — | — | US | disclosed |
| US-12473304-B2 | Heterocyclic PAD4 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-11-18 | — | — | US | disclosed |
| WO-2025233863-A1 | ENPP1 INHIBITORS | RE VENTURES I, LLC (US) | 2025-11-13 | — | — | WO | disclosed |
| US-20250282742-A1 | BENZOFURAN DERIVATIVES FOR TARGETING AUTOPHAGY | Automera PTE. LTD (SG) | 2025-09-11 | — | — | US | disclosed |
| WO-2025151449-A1 | BIFUNCTIONAL P53-BINDING COMPOUNDS AND USES THEREOF | PHOTYS THERAPEUTICS, INC. (US) | 2025-07-17 | — | — | WO | disclosed |
| WO-2025054408-A1 | METHODS OF TREATING COGNITIVE IMPAIRMENT | NeuroTherapia, Inc. (US) | 2025-03-13 | — | — | WO | disclosed |
| US-20250082624-A1 | METHODS OF TREATING COGNITIVE IMPAIRMENT | NeuroTherapia, Inc. | 2025-03-13 | — | — | US | disclosed |
| US-5981776-A | FOR USE IN HUMAN OR VETERINARY MEDICINE (DERMATOLOGICAL, RHEUMATIC, RESPIRATORY, CARDIOVASCULAR AND OPHTHALMOLOGICAL COMPLAINTS IN PARTICULAR), OR ALTERNATIVELY IN COSMETIC COMPOSITIONS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) | 1999-11-09 | — | — | US | disclosed |
| EP-0951285-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 1999-10-27 | — | — | EP | disclosed |
| US-5939439-A | Inhibitors of farnesyl-protein transferase | MERCK & CO., INC. (US) | 1999-08-17 | — | — | US | disclosed |
| WO-1999017777-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1999-04-15 | — | — | WO | disclosed |
| WO-1999010524-A1 | A METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 1999-03-04 | — | — | WO | disclosed |
| WO-1999010525-A1 | A METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 1999-03-04 | — | — | WO | disclosed |
| WO-1999010523-A1 | A METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 1999-03-04 | — | — | WO | disclosed |
| WO-1999009985-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1999-03-04 | — | — | WO | disclosed |
| WO-1998029119-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1998-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062443-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | C9, SSB, C1S | CA1 2829/4885CA2 2290/4885CA12 1850/4885 |
| US-12473304-B2 | Heterocyclic PAD4 inhibitors | PADI6, PADI4, PADI1 | CA1 3116/4885CA2 4284/4885CA12 3948/4885 |
| US-20250082624-A1 | METHODS OF TREATING COGNITIVE IMPAIRMENT | CHAT, NLN, NEFM | CA1 460/4885CA2 2201/4885CA12 1970/4885 |
| US-20250282742-A1 | BENZOFURAN DERIVATIVES FOR TARGETING AUTOPHAGY | SQSTM1, BECN1, TFEB | CA1 4394/4885CA2 3307/4885CA12 4558/4885 |
| US-20260001886-A1 | ENPP1 INHIBITORS I | ENPP1, ENPP2, ENPP3 | CA1 4636/4885CA2 3450/4885CA12 4828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.